NEW YORK (Reuters Health) Aug 27 –
In broad clinical experience in Sweden, etanercept proved superior to leflunomide and probably infliximab for treating rheumatoid arthritis, according to a report in the September issue of Annals of Rheumatic Diseases.
Rheumatoid arthritis often is treated with cytokine-modifying therapy with tumor necrosis factor (TNF) blockade by etanercept or infliximab, or with pyrimidine synthesis inhibitor leflunomide, the authors explain, but the treatments have not been compared directly in open clinical trials involving a broad spectrum of patients.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!